Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the completion of a US $320 million private financing round. The oversubscribed round includes new investors, Woodford Investment Management, Malin Corporation plc, Eli Lilly and Company and RTW Investments, as well as a number of new and existing investors in Immunocore.